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Mucosalmelanoma of the head and neck accounts for only 25
to 30% of total melanomas with sinonasal melanoma ac-
counting for less than 5% of these. Sinonasal melanoma
carries a relatively poor prognosis, owing to the tendency
of sinonasal melanoma to present at an advanced stage. A
standardized treatment regimen has been difficult to devel-
op, owing to the low incidence of the disease. Typically
sinonasal melanoma has been thought to be a radiation-
resistant disease, and thus surgical resection with clear
margins has been the key component of therapy with cura-
tive intent, while chemotherapy and immunotherapy have
typically been reserved for unresectable or metastatic dis-
ease. Recent literature has suggested, however, that there
may be a 50 to 75% initial response rate when radiotherapy
alone is used.1 It has not been shown definitively that there is
a survival advantage with the addition of radio- or chemo-
therapy to surgery. One of our primary aims was to deter-
mine whether there is a statistically significant increase in
survival with combined therapy versus single modality
therapy. In addition, we sought to characterize the most
frequent primary site location, as well as the frequency of






Abstract Sinonasal melanoma is an uncommon tumor which carries a poor prognosis and high
rates of local and regional recurrence and distant metastasis. While surgical resection is
the mainstay of treatment, the utility of multimodality therapy has not been well
studied or established.We sought to better evaluate the optimal treatmentmodality for
sinonasal melanoma. We reviewed 39 case reports involving 423 patients with sinonasal
melanoma and present a meta-analysis comparing survival by treatment modality. The
two-tailed p-value for survival by treatment modality was determined. The number of
primary site/local, regional, and distant recurrences was determined where data was
available. There was a nonsignificant increase in survival for patients treated with
surgery þ radiotherapy versus surgery alone. There was a statistically significant
increase in survival for surgery þ chemotherapy versus chemotherapy alone and versus
surgery alone. Patients treated with combined surgery, radiation, and chemotherapy
had a statistically shorter survival interval than patients treated with surgery þ che-
motherapy, which may reflect more advanced disease in patients treated with triple
therapy. There was no statistically significant increase in survival found for the addition
of radiation to surgery. This meta-analysis demonstrates that multimodality therapy,
particularly the addition of chemo-or immunotherapy to surgery, may increase survival
in a subset of patients. Radiation therapy did not appear to increase survival. There may
be a significant increase in overall survival with combined modality therapy with surgery
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Average survival was calculated as the average of the longest
survival reported for each patient in each treatment group.
Chemotherapy and immunotherapy were grouped together
in the chemotherapy group. Two-sided p-values for survival
were calculated using the Student’s t-test with values <0.05
considered significant.
Results
Thirty-nine reviews, case series, and case reports were stud-
ied totaling 423 patientswith sinonasalmelanoma.2–40Of the
206 patients for whom treatment and survival data was
provided, 53 patients were treated with surgery alone, while
91 were treated with surgery and radiotherapy and 26
patients were treated with surgery along with chemoradia-
tion. Fifteen patients were treated with radiotherapy alone
whereas 3 patients were treated with chemotherapy alone,
15 patients were treated with surgery plus chemotherapy,
and 3 patients were treated with chemoradiation. ►Table 1
shows average survival by treatment modality,
whereas ►Table 2 shows p-values for comparisons between
treatment modalities. The average survival was 24.15months
for surgery alone, 30.12months for surgery and radiotherapy,
and 23.45 months for surgery and chemoradiation. The two-
tailed p-value was not significant for any of these differences
in survival. The average survival for radiotherapy, chemother-
apy, surgery þ chemotherapy, and chemoradiotherapy was
18.73, 12.67, 38.83, and 38.67 months respectively. Of these,
the increases in survival interval between surgery þ chemo-
therapy and both chemotherapy alone and surgery alone
were statistically significant, with p-values of 0.0205 and
0.0112, respectively. There was also a statistically significant
decrease in survival for patients treated with surgery, radia-
tion, and chemotherapy versus patients treated with surgery
and chemotherapy, with a p-value of 0.0387.
Of the 423 patients, there were 17 patients specifically
reported to have metastases to the neck, but 36 reported
regional metastases. Two hundred and six recurrences were
reported, for a recurrence rate of 54.6%. The most common
primary site was the nasal cavity/nasopharynx with 165
cases. Unspecified sinus was next most frequent with 54
cases, followed by turbinate unspecifiedwith 34 and the nasal
septum with 33 cases.
Table 1 Average Survival (Months) by Treatment Modality
Modality n Average Survival (Months) Standard Deviation
Surgery 53 24.15 19.78
Surgery þ Radiotherapy 91 30.12 29.27
Surgery þ Radiotherapy þ Chemotherapy 26 23.45 24.56
Radiotherapy 15 18.73 17.66
Chemotherapy 3 12.7 5.8
Surgery þ Chemotherapy 15 38.8 17.1
Chemotherapy þ Radiotherapy 3 38.7 40.3
Table 2 Two-Tailed p-Value by Treatment Modality
Modality Two-Tailed p-Value for Overall Survival
Surgery survival vs. surgery þ radiotherapy survival 0.1895
Surgery survival vs. triple therapy survival 0.8925
Surgery þ radiotherapy survival vs. triple therapy survival 0.2921
Surgery survival vs. radiotherapy survival 0.3421
Surgery þ radiotherapy survival vs. radiotherapy survival 0.1474
Triple therapy survival vs. radiotherapy survival 0.5182
Chemotherapy þ radiotherapy survival vs. chemotherapy alone survival 0.3305
Surgery þ chemotherapy survival vs. chemotherapy alone survival 0.0205a
Surgery survival vs. chemotherapy survival 0.3242
Triple therapy survival vs. chemotherapy survival 0.4615
Surgery þ chemotherapy survival vs. surgery alone survival 0.0112a
Triple therapy survival vs. surgery þ chemotherapy survival 0.0387a
Chemotherapy þ surgery vs. chemotherapy þ radiation survival 0.9907
aStatistically significant.
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Discussion
The question of whether to add radiation and chemotherapy
to surgery in treatment of nasalmelanomahas been a difficult
question to answer. Given the low incidence of melanoma of
the sinonasal cavity it is difficult to assemble randomized
control trials or even large case-control studies. Sinonasal
melanoma has been thought to be a radioresistant disease,
with surgery with negative margins being the primary mo-
dality for attempted cure. We sought to elucidate whether
combined therapy increased survival in primary sinonasal
melanoma over single modality therapy. We performed a
meta-analysis of 423 patients with histologically confirmed
sinonasal melanoma. The majority of patients (135/206) for
whomdata on treatmentmodalitywas providedwere treated
with some form of combined modality therapy. The majority
were treated with surgery þ radiation or surgery alone. No
significant difference was seen between surgery or combined
surgery þ radiation. Interestingly, survival was actually de-
creased for patients treated with surgery, radiation, and
chemotherapy, although this difference was nonsignificant
versus surgery alone or surgery þ radiation, but was signifi-
cant versus surgery þ chemotherapy (23.45months vs. 38.83
months, p ¼ 0.0387). This may reflect a higher stage of
disease in patients treated with triple therapy. This hypothe-
sis is difficult to confirm as only two studies reported the
specific stage for patients in these two treatment groups, with
three patients in both the triple therapy and surgery þ che-
motherapy group noted to have metastatic disease and no
specific data on stage available for the remainder of the
patients in these two treatment groups. As might be ex-
pected, the shortest survival was found for chemotherapy
alone at 12.7 months. This difference was not significant for
chemotherapy alone versus surgery alone or radiation alone.
There was, however, a statistically significant (p ¼ 0.0205)
increase in survival for surgical treatment þ chemotherapy
(38.82  17.05 months) versus chemotherapy alone
(12.7  5.8 months). There was also a statistically significant
increase in survival for surgery þ chemotherapy versus sur-
gery alone (24.15  19.78, p-value ¼ 0.0112). Other than the
statistically significant increase in survival for surgery þ che-
motherapy versus chemotherapy alone and surgery alone,
and the decreased survival in patients treated with triple
modality therapy versus surgery þ chemotherapy, no signif-
icant increase in survival was seen for any other single-or
multimodality therapy. This is consistent with previous data
showing that radiotherapy adds little to overall survival in
sinonasal melanoma.
The vast majority of primary sinonasal melanomas oc-
curred in the nasal cavity or nasopharynx. The most common
sinus primaries were maxillary and ethmoid, with primary
sphenoid sinonasal melanoma being quite rare, with only five
cases seen. Average survival for all modalities was
27.41  24.32 months. This number is consistent with other
studies showing an average survival of 2 years.41
Distant metastases were by far the most common site of
recurrence (90, 44%), with locoregional (45, 22%), regional
(36, 17%), and local (35, 17%) recurrence much less prevalent
than distantmetastases. The rate of regionalmetastasis in this
meta-analysis is consistent with the 5 to 25% range found in
most series. Given this relatively low rate in sinonasal mela-
noma, elective neck dissection has not been widely advocat-
ed, in contrast to oral cavity mucosal melanoma, which
carries a much higher rate of nodal metastasis.10,42
This seems to indicate that evenwith good local or regional
control, sinonasal melanoma is difficult to control as distant
spread is likely to occur even in the presence of good locore-
gional control. This is consistent with other reports41,43
indicating that even after extensive surgical resection, local
control has been reported to be below 50%, and that distant
and regional metastases are relatively common, occurring in
25% or more patients in most series.41,43 This may at least
partially explain the lack of survival benefit with combined
modality therapy versus single modality therapy. The pro-
pensity for recurrence is so high that significant improve-
ments in local or locoregional control with combined therapy
are likely lost due to the high frequency of recurrence,
particular of distant recurrence/metastasis.
Ninety percent of the patients in this meta-analysis (185/
206 patients) for whom treatment datawas reported received
some form of surgical therapy. Our data and previous reports
indicate that while surgery is the primary modality for
treatment of sinonasal melanoma, survival remains poor
even in patients with gross local control, likely secondary
to both the high rate of distant metastases (44% in our data)
along with the high rate of microscopic disease.43 Patients
with positive surgical margins have a greatly increased risk of
dying from mucosal melanoma, and lack of local control has
been shown to increase the rate of distant metastases.44 The
poor survival in sinonasal melanoma even with aggressive
surgical management in the vast majority of patients may
result from the presence of microscopic disease as well as
occult distant metastases.
Fifteen of 206 patients (7%) were treated with radiothera-
py alone, while 91 of 206 (44%) were treated with adjuvant
radiotherapy with surgery, and 26/206 (13%) with triple
therapy and 3/206 (0.01%) with chemoradiation. Adjuvant
radiotherapy has become widely used in sinonasal melano-
ma, despite the lack of clear evidence of a survival benefit.
Temam et al45 found that while adjuvant radiotherapy pro-
duced a statistically significant increase in local control in
head and neck melanoma, the rate of distant metastasis and
disease-free survival was not affected in a statistically signifi-
cant fashion. Krengli et al46 and Owens et al47 found similar
results, with radiation improving local and locoregional
control, but not affecting overall survival. We similarly found
no statistically significant increase in overall survival for the
addition of radiation to any other modality, or as primary
therapy. Sufficient data was not available on our meta-
analysis population to examine the effect of either adjuvant
or primary radiation on local or locoregional control. Owens
et al felt that the lack of improvement in overall survival with
either primary radiation or adjuvant radiotherapy was due to
the high rate of metastatic disease in these series. This seems
to be a likely explanation, as in our meta-analysis we noted
that the majority of recurrences (90) were distant
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recurrences, which is consistent with the high rate of metas-
tasis seen in these prior studies.
In ourmeta-analysis 3 of 206 patients (0.01%) were treated
with chemotherapy or immunotherapy alone, 3 of 206
(0.01%) with chemotherapy with radiotherapy, 15/206 with
surgery þ chemotherapy (0.07%), and 26/206 (0.12%) with
triple therapy.We observed a statistically significant increase
in survival for surgery þ chemotherapy versus both chemo-
therapy alone and surgery alone. We also noted a statistically
significant decrease in survival for patients treatedwith triple
therapy versus surgery þ chemotherapy only. Due to the lack
of specific data given on the immunotherapy or chemothera-
py regimen given on each patient, we grouped chemotherapy
and bio- or immunotherapy together. There is no standard-
ized systemic therapy for sinonasal melanoma, and many
patients are treated with a chemotherapeutic agent in con-
junction with a biologic or immunotherapeutic agent such as
Bacillus Calmette-Guérin, interferon-α, or interleukin-2. Ives
et al examined the effectiveness of chemotherapy versus
immunotherapy in patients with metastatic cutaneous mela-
noma.48 They specifically examined the effect of adding
interferon-α (IFN)  interleukin-2 (IL-2) to chemotherapy
in patients with metastatic melanoma. Their meta-analysis
of trials of biochemotherapy versus chemotherapy evaluated
rates of partial response, complete response and overall
(partial þ complete) response; response duration; progres-
sion-free survival, overall survival, and toxicity. A subgroup
analysiswas performed by type of immunotherapy, according
to whether IFN only or IFN and IL-2 were administered in the
biochemotherapy arm. They found a clear benefit for bio-
chemotherapy for partial, complete, and overall response for
both the IFN and IFN þ IL-2 groups. They found no benefit in
overall survival for biochemotherapy versus chemotherapy.
There was a significant heterogeneity in the types of chemo-
therapy utilized. Most trials used a single-agent chemother-
apy regimen, DTIC, temozolomide, or vindesine. One trial
used combination aranoza and cisplatin. The trials of chemo-
therapy  IFN and IL-2 used combination DTIC and cisplatin
or a triple chemotherapy regimen of DTIC and cisplatin
combined with carmustine, vinblastine, or vindesine. The
studies included in our meta-analysis did not provide consis-
tent data on the specific regimen used.
Data on chemotherapy and biochemotherapy in sinonasal
melanoma is limited. Bartell et al49 reported on 15 patients
who received various biochemotherapy regimens for ad-
vanced head and neck mucosal melanoma. After a median
follow-up of 13months, 3 patients (20%) had partial response,
and 4 patients (27%) had complete response. Themedian time
to disease progression for all 15 patients was 10 months and
the median overall survival duration for all patients was
22 months. They concluded that biochemotherapy for ad-
vanced head and neck mucosal melanoma should be consid-
ered as a systemic treatment option both as adjuvant therapy
for metastatic disease as well as neoadjuvant therapy for
patients with aggressive or extensive local disease.
The decrease in survival for triple therapy versus surgery
þ chemotherapy in our datamaywell be due to a higher stage
in the triple therapy group. It is difficult to definitively answer
this due to the limited patient-specific data available in the
manuscripts analyzed. The statistically significant increase in
overall survival for surgery þ chemo- or biochemotherapy
versus surgery alone and chemotherapy alone is, to our
knowledge, thefirst demonstrated increase in overall survival
in sinonasal melanoma for combined therapy. It seems likely
that this is due to response to chemo- and biochemotherapy
of metastatic disease, as several studies have demonstrated
the lack of improvement in overall survival with improve-
ment in local control. Again, the limited patient-specific data
provided makes this difficult to establish, but it seems clear
that systemic therapy improves overall survival while the
addition of radiotherapy does not significantly improve over-
all survival, but may improve local control.
There are several weaknesses of this study. First, the
retrospective data makes selection bias a possibility. Howev-
er, it is extremely difficult to assemble single- or multicenter
prospective trials for uncommon tumors such as sinonasal
melanoma. A randomized prospective multicenter trial for
sinonasalmelanomawould potentially allowbetter standard-
ization of treatment regimens as well as more accurate
comparison of local control, disease-free survival, and overall
survival between treatment modalities. The varying lengths
of follow-up is another issue, however most studies followed
patients for several years, and in many cases the case series
included patients over the course of a decade. Given the
relatively constant average survival for sinonasal melanoma,
2 years, we believe this gives fairly accurate longitudinal
follow-up in the data included in our meta-analysis. Another
weakness is the inclusion of chemotherapy with biochemo-
therapy and immunotherapy as a single group. A more
specific subgroup analysis by specific treatment regimen
would be ideal, however the limited number of patients
with sinonasal melanoma and the lack of individual data on
each patient makes this difficult. As other large series such as
the Ivesmeta-analysis48 grouped different regimens together
and found significant differences which were maintained
whether the chemo- and biochemotherapy groups were
analyzed separately or as subgroups, we believe this does
not significantly affect the overall improvement on survival
found in this meta-analysis.
Conclusion
To our knowledge, this is the largest meta-analysis of patients
with primary sinonasal melanoma. The data demonstrates
that there is no survival advantage for combined radiotherapy
þ surgery or chemoradiotherapy þ surgery versus surgery
alone. We did find a significant overall survival advantage for
surgery þ chemotherapy versus surgery alone and versus
chemotherapy alone. The average overall survival was
27.41months for all therapies, confirming past studies point-
ing to a fairly dismal prognosis for this rare malignancy. We
therefore recommend aggressive treatment primarily with
surgery for resectable disease with the goal of achieving local
control, with the caveat that a significant number of patients
will have distant recurrence (44% in our dataset) which is not
significantly impacted by adjuvant treatment such as
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radiotherapy. It appears that improvements in overall surviv-
al must result from improvements in response of metastatic
disease and distant recurrences with chemotherapy, immu-
notherapy, or biochemotherapy. We recommend aggressive
surgical resection as the primary modality, combined with
radiotherapy as necessary for local control. We recommend
chemotherapy and biochemotherapy as both adjuvant treat-
ment for distant disease as well as neoadjuvant chemothera-
py as this appears to improve overall survival. In conclusion,
this meta-analysis is, to our knowledge, the largest meta-
analysis of patients with mucosal melanoma of the nasal
cavity/paranasal sinuses. It confirms earlier retrospective
studies demonstrating that sinonasal melanoma has a poor
prognosis, with survival on the order of 24 months. It also
demonstrates that the addition of radiotherapy to surgical
resection does not significantly improve overall survival, but
that overall survival is improved with combined
surgery þ chemotherapy.
Note
Presented at the 20th Annual North American Skull Base
Society Meeting, New Orleans, LA, October 14th to 18th,
2009.
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